<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166579">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02012998</url>
  </required_header>
  <id_info>
    <org_study_id>HXV02C</org_study_id>
    <secondary_id>2013-001602-28</secondary_id>
    <nct_id>NCT02012998</nct_id>
  </id_info>
  <brief_title>Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA</brief_title>
  <official_title>An Open-label, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO to Explore the Anamnestic Immune Response in Healthy Children Vaccinated 10 Years Ago With a Primary Series (3 Doses) of Either HEXAVAC or INFANRIX HEXA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur MSD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi Pasteur MSD</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the  immune response to Hepatitis B virus in children who have been primed with
      HEXAVAC or INFANRIX HEXA 10 years ago.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Percentage of subjects with an anti-hepatitis B concentration ≥10 mIU/mL</measure>
    <time_frame>One month after the challenge dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with an anti-hepatitis B concentration ≥10 mIU/mL</measure>
    <time_frame>Prior to challenge dose (At Day 0 prior to administration of the challenge dose)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited injection-site adverse reactions and pyrexia</measure>
    <time_frame>Day 0 to day 4 after vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited injection-site adverse reactions and systemic adverse events</measure>
    <time_frame>Day 0 to day 14 after vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>From signature of the informed consent to the last visit of the subject, an expected average of one month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Virus Diseases</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HBVAXPRO Challenge dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBVAXPRO 5µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBVAXPRO 5µg</intervention_name>
    <description>0.5mL intramuscular injection</description>
    <arm_group_label>HBVAXPRO Challenge dose</arm_group_label>
    <other_name>Hepatitis B vaccine (rDNA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy child

          -  Child vaccinated with 3 doses of HEXAVAC or 3 doses of INFANRIX HEXA as infant

          -  Child vaccinated with the third dose of HEXAVAC or INFANRIX HEXA at least 10 years
             prior to challenge dose

        Exclusion Criteria:

          -  Receipt of more than 3 doses of any Hepatitis B containing vaccine

          -  History of clinical diagnosis of infection due to Hepatitis B

          -  History or current close contact with known carriers of Hepatitis B virus

          -  Prior known sensitivity or allergy to any component of HBVAXPRO

          -  Chronic illness / medical condition that could interfere with study conduct or
             completion

          -  Coagulation disorder that would contraindicate intramuscular injection

          -  Subject is pregnant

          -  Receipt of corticosteroids for more than 14 days in the 30 days prior to study

          -  Receipt of Immunoglobulins, blood or blood-derived products in the 3 months prior to
             study

          -  Planned participation in another clinical study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florence BOISNARD, PhD</last_name>
    <email>clinicaldevelopment@spmsd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie WEHRLEN-GRANDJEAN, MD</last_name>
    <email>clinicaldevelopment@spmsd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 004</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 009</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 005</name>
      <address>
        <city>Capannori</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 003</name>
      <address>
        <city>Chiavari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 002</name>
      <address>
        <city>Latisana</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 008</name>
      <address>
        <city>Massafra</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 006</name>
      <address>
        <city>Nocera Inferiore</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 010</name>
      <address>
        <city>Ragusa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 007</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 001</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>December 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
